Midline catheters — A good alternative device?

Marsh, Nicole; Corley, Amanda; Schults, Jessica; Vemuri, Kanti; Rickard, Claire M

doi:10.1016/j.accpm.2021.100885

Cited by 6 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few reports have assessed the risk of phlebitis from PIVCs inserted into the upper extremities, and the risk remains unknown. Similar to midline catheters and peripherally inserted central catheters (PICCs) inserted into the upper extremities [40], PIVCs inserted in the upper arm are generally placed in large-diameter vessels to facilitate natural hemodilution of IV drugs and reduce the likelihood of chemical phlebitis [41]. This could be attributed to the following mechanisms: first, the mechanisms underlying phlebitis is mechanical stimulation of the vascular wall by catheters [42,43], and catheters inserted in highly mobile areas, such as the hand and forearm may cause phlebitis due to the increased stress on the vascular wall if the catheter is not firmly fixed [44].…”

Section: Discussionmentioning

confidence: 99%

Risk factors for peripheral intravascular catheter-related phlebitis in critically ill patients: analysis of 3429 catheters from 23 Japanese intensive care units

Yasuda

Rickard

Marsh

et al. 2022

Ann. Intensive Care

Self Cite

View full text Add to dashboard Cite

Background Phlebitis is an important complication occurring in patients with peripheral intravascular catheters (PIVCs). The risk factors for phlebitis in the intensive care unit (ICU) was examined. Methods A secondary analysis of a prospective multicenter cohort study was conducted, involving 23 ICUs in Japan—the AMOR–VENUS study. Consecutive patients aged ≥ 18 years admitted to the ICU with newly inserted PIVCs after ICU admission were enrolled. Characteristics of the ICU, patients, PIVCs, and the drugs administered via PIVCs were recorded. A marginal Cox regression model was used to identify the risk factors associated with phlebitis. Results A total of 2741 consecutive patients from 23 ICUs were reviewed for eligibility, resulting in 1359 patients and 3429 PIVCs being included in the analysis population. The median dwell time was 46.2 h (95% confidence interval [CI], 21.3–82.9). Phlebitis occurred in 9.1% (95% CI, 8.2–10.1%) of catheters (3.5 cases/100 catheter days). The multivariate analysis revealed that the only factors that increased the risk of developing phlebitis were drugs administered intravenously. This study included 26 drugs, and 4 were associated with increased phlebitis: nicardipine (HR, 1.85; 95% CI, 1.29–2.66), noradrenaline (HR, 2.42; 95% CI, 1.40–4.20), amiodarone (HR, 3.67; 95% CI, 1.75–7.71) and levetiracetam (HR, 5.65; 95% CI, 2.80–11.4). Alternatively, factors significantly associated with a reduced risk of phlebitis were: standardized drug administration measures in the ICU (HR, 0.35; 95% CI, 0.17–0.76), 30≤ BMI (HR, 0.43; 95% CI, 0.20–0.95), catheter inserted by a doctor as nurse reference (HR, 0.55; 95% CI, 0.32–0.94), and upper arm insertion site as forearm reference (HR, 0.52; 95% CI, 0.32–0.85). The nitroglycerin was associated with a reduced phlebitis risk (HR, 0.22; 95% CI, 0.05–0.92). Conclusion Various factors are involved in the development of phlebitis caused by PIVCs in critically ill patients, including institutional, patient, catheter, and drug-induced factors, indicating the need for appropriate device selection or models of care in the ICU. Trial registration: UMIN-CTR, the Japanese clinical trial registry (registration number: UMIN000028019, July 1, 2017).

show abstract

Section: Discussionmentioning

confidence: 99%

Risk factors for peripheral intravascular catheter-related phlebitis in critically ill patients: analysis of 3429 catheters from 23 Japanese intensive care units

Yasuda

Rickard

Marsh

et al. 2022

Ann. Intensive Care

Self Cite

View full text Add to dashboard Cite

show abstract

Comparing the use of midline catheters versus peripherally inserted central catheters for patients requiring peripherally compatible therapies: A pilot randomised controlled trial (the compact trial)

Marsh

Larsen

O’Brien

et al. 2023

Infection, Disease & Health

View full text Add to dashboard Cite

Development of an Evidence-Based List of Non-Antineoplastic Vesicants

Gorski,

Ong,

Van Gerpen

et al. 2024

Journal of Infusion Nursing

View full text Add to dashboard Cite

Infiltration of a vesicant, called extravasation, can result in severe patient injuries. Recognition of vesicants and their relative risk of injury is essential to extravasation prevention, early recognition, and appropriate treatment. In this article, the Vesicant Task Force (VTF) updates the previously published Infusion Nurses Society (INS) vesicant list from 2017. The 2024 INS list diverges from earlier vesicant lists, such as the 2017 VTF list, by adopting a risk stratification approach based upon documented patient outcomes, in contrast to the reliance on expert consensus or only surrogate risk indicators, such as pH and osmolarity. The methodology used to create the updated list is explained, and the criteria for high- and moderate-risk vesicants and cautionary vesicants are defined.

show abstract

Midline catheters — A good alternative device?

Cited by 6 publications

References 20 publications

Risk factors for peripheral intravascular catheter-related phlebitis in critically ill patients: analysis of 3429 catheters from 23 Japanese intensive care units

Risk factors for peripheral intravascular catheter-related phlebitis in critically ill patients: analysis of 3429 catheters from 23 Japanese intensive care units

Comparing the use of midline catheters versus peripherally inserted central catheters for patients requiring peripherally compatible therapies: A pilot randomised controlled trial (the compact trial)

Development of an Evidence-Based List of Non-Antineoplastic Vesicants

Contact Info

Product

Resources

About